Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Pfizergan Would Have Challenged Novartis For 2015 Approvals Crown

Executive Summary

Novartis had the most new molecular entity approvals in 2015 with four, all developed in house; next in line is Allergan, with three approvals that stem from acquisitions and licensing.


Related Content

No Dominant Sponsors In US FDA's 2016 Novel Approvals Class


Related Companies

Related Deals